Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $2.18B |
| Gross Profit (TTM) | $470.80M |
| EBITDA | $46.18M |
| Operating Margin | 49.00% |
| Return on Equity | 4.91% |
| Return on Assets | 0.02% |
| Revenue/Share (TTM) | $21.41 |
| Book Value | $14.26 |
| Price-to-Book | 1.10 |
| Price-to-Sales (TTM) | 0.77 |
| EV/Revenue | 0.933 |
| EV/EBITDA | 16.31 |
| Quarterly Earnings Growth (YoY) | 2664.00% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $105.58M |
| Float | $94.61M |
| % Insiders | 4.21% |
| % Institutions | 99.55% |
Volatility is currently contracting
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta's Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transiti.
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentati.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against certain of its officers and directors for alleged breaches of fiduciary duty.
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action data of February 28, 2027. The sNDA.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SRPT and any ticker you trade — then tracks every position and per-strategy win rate.
